Construction and evaluation of drug-metabolizing cell line for bioartificial liver support system

Biotechnology Progress

Volumn 21, Issue 1, 2005, Pages 161-167

  Omasa, Takeshi ^a   Kim, Kazumi ^a   Hiramatsu, Shinya ^a   Katakura, Yoshio ^a   Kishimoto, Michimasa ^a   Enosawa, Shin ^b   Ohtake, Hisao ^a  

^a OSAKA UNIVERSITY   (Japan)

^b NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMIMETIC MATERIALS; CELLS; ENZYMES; GENES; METABOLISM; MODULAR CONSTRUCTION;

BIOARTIFICIAL LIVERS (BAL) SUPPORT SYSTEM; CELL-LINES; GLUTAMATE SYNTHETASE; HUMAN PRIMARY HEPATOCYTES;

DRUG DOSAGE;

AMMONIA; CYP3A PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450; DIMERCAPROL; GLUTAMATE AMMONIA LIGASE; RECOMBINANT PROTEIN;

ANIMAL; ARTICLE; ARTIFICIAL LIVER; BIOREACTOR; CELL CULTURE; CHO CELL; CULTURE TECHNIQUE; GENETIC TRANSFECTION; GENETICS; HAMSTER; HUMAN; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; TUMOR CELL LINE;

AMMONIA; ANIMALS; BIOREACTORS; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELLS, CULTURED; CHO CELLS; CRICETINAE; CYTOCHROME P-450 ENZYME SYSTEM; DIMERCAPROL; GLUTAMATE-AMMONIA LIGASE; HUMANS; LIVER, ARTIFICIAL; METABOLIC CLEARANCE RATE; RECOMBINANT PROTEINS; TRANSFECTION;

EID: 13544260643     PISSN: 87567938     EISSN: None     Source Type: Journal    
DOI: 10.1021/bp049757a     Document Type: Article

References (39)

1. Strain, A. J.; Neuberger, J. M. A bioartificial liver-state of the art. Science 2002, 295, 1005-1009.
2. Sauer, I. M.; Obermeyer, N.; Kardassis, D.; Theruvath, T.; Gerlach, J. C. Development of a hybrid liver support system. Ann. N.Y. Acad. Sci. 2001, 944, 308-319.
3. Stange, J.; Mitzner, S.; Cell sources for bioartificial liver support. Int. J. Artif. Organs 1996, 19, 14-17.
4. Kang, Y. H.; Berthiaume, F.; Nath, B. D.; Yarmush, M. L. Growth factors and nonparenchymal cell conditioned media induce mitogenic responses in stable long-term adult rat hepatocyte cultures. Exp. Cell Res. 2004, 293, 239-247.
5. Mizumoto, H.; Funatsu, K. Liver regeneration using a hybrid artificial liver support system. Artif. Organs 2004, 28, 53-57.
6. Sussman, N. L.; Killy, J. H. Improved liver function following treatment with an extracorporeal liver assist device. Artif. Organs 1993, 17, 27-30.
7. Omasa, T.; Yamanaka, M.; Tanimura, N.; Katakura, Y.; Kishimoto, M.; Suga, K.; Enosawa S. Expression and amplification of glutamine synthetase gene endows HepG2 cells with ammonia-metabolizing activity for bioartificial liver support system. Enzyme Microb. Technol. 2004, 35, 519-524.
8. Enosawa, S.; Miyashita, T.; Suzuki, S.; Li, X. K.; Tsunoda, M.; Amemiya, H.; Yamanaka, M.; Hiramatsu, S.; Tanimura, N.; Omasa, T.; Suga K.; Matsumura, T. Long-term culture of glutamine synthetase-transfected HepG2 cells in circulatory flow bioreactor for development of a bioartificial liver. Cell Transplant. 2000, 9, 711-715.
9. Miyashita, T.; Enosawa, S.; Suzuki, S.; Tamura, A.; Tanaka, H.; Amemiya, H.; Matsumura, T.; Omasa, T.; Suga, K.; Aoki, T.; Koyanagi, Y. Development of a bioartificial liver with glutamine synthetase-transduced recombinant human hepatoblastoma cell line, HepG2. Transplant. Proc. 2000, 32, 2355-2358.
10. Enosawa, S.; Miyashita, T.; Fujita, Y.; Suzuki, S.; Amemiya, H.; Omasa, T.; Hiramatsu, S.; Suga, K.; Matsumura, T. In vivo estimation of bioartificial liver with recombinant HepG2 cells using pigs with ischemic liver failure. Cell Transplant. 2001, 10, 429-433.
11. Enosawa, S.; Miyashita, T.; Tanaka, H.; Li, X.; Suzuki, S.; Amemiya, H.; Omasa, T.; Suga, K.; Matsumura, T.; Prolongation of survival of pigs with ischemic liver failure by treatment with a bioartificial liver using glutamine synthetase transfected recombinant HepG2. Transplant. Proc. 2001, 33, 1945-1947.
12. Tzanakakis, E. S.; Hsiao, C. C.; Matsushita, T.; Remmel, R. P.; Hu, W. S. Probing enhanced cytochrome P450 2B1/2 activity in rat hepatocyte spheroids through confocal laser scanning microscopy. Cell Transplant. 2001, 10, 329-342.
13. Maurel, P The CYP3 family. In Cytochromes P450 Metabolic and Toxicological Aspects; Ioannides, C., Ed.; CRC Press: London, 1996; pp 241-270.
14. Wortelboer, H. M.; de Kruif, C. A.; van Iersel, A. A.; Falke, H. E.; Noordhoek, J.; Blaauboer, B. J.; The isoenzyme pattern of cytochrome P450 in rat hepatocytes in primary culture, comparing different enzyme activities in microsomal incubations and in intact monolayers. Biochem. Pharmacol. 1990, 40, 2525-2534.
15. Omasa, T.; Ishimoto, M.; Higashiyama, K.; Shioya, S.; Suga, K. The effects of glutamine concentration on growth and monoclonal antibody production in fed-batch operation. Cytotechnology 1992, 8, 75-84.
16. Omasa, T.; Higashiyama, K.; Shioya, S.; Suga, K. Effect of lactate concentration on hybridoma culture in lactate-controlled fed-batch operation. Biotechnol. Bioeng. 1992, 39, 556-564.
17. De Groene, E. M.; Seinen, W.; Horbach, G. J. A NIH/3T3 cell line stably expressing human cytochrome P450-3A4 used in combination with a lacZ′ shuttle vector to study mutagenicity. Eur. J. Pharmacol. 1995, 26, 47-53.
18. Kozak, M. Downstream secondary structure facilitates recognition of initiator codons by eukaryotic ribosomes. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 8301-8305.
19. Rowe, W. B.; Ronzio, R. A.; Wellener, V. P.; Meister, A. Glutamine synthetase (Sheep brain). Methods Enzymol. 1970, 17a, 901-910.
20. Williams, J. A.; Chenery, R. J.; Hawksworth, G. M. Induction of CYP3A enzymes in human and rat hepatocyte cultures. Biochem. Soc. Trans. 1994, 22, 131S.
21. Donato, M. T.; Castell, J. V.; Gómez-Lechón, M. J. Characterization of drug metabolizing activities in pig hepatocytes for use in bioartificial liver devices: comparison with other hepatic cellular models. J. Hepatol. 1999, 31, 542-549.
22. Pearce, R. E.; McIntyre, C. J.; Madan, A.; Sanzgiri, U.; Draper, A. J.; Bullock, P. L.; Cook, D. C.; Burton, L. A.; Latham, J.; Nevins, C.; Parkinson, A. Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity. Arch. Biochem. Biophys. 1996, 331, 145-169.
23. Hamilton, G. A.; Jolley, S. L.; Gilbert, D.; Coon, D. J.; Barros, S.; LeCluyse, E. L. Regulation of cell morphology and cytochrome P450 expression in human hepatocytes by extracellular matrix and cell-cell interactions. Cell Tissue Res. 2001, 306, 85-99.
24. Price, J. M.; Miller, E. C.; Miller J. A. The intracellular distribution of protein, nucleic acids, riboflavin, and protein-bound aminoazo dye in the livers of rats fed p-dimethylaminoazobenzene. J. Biol. Chem. 1948, 173, 345-353.
25. Fukuda, J.; Okamura, K.; Nakazawa, K.; Ijima, H.; Yamashita, Y.; Shimada, M.; Shirabe, K.; Tsujita, E.;, Sugimachi, K.; Funatsu, K.; Efficacy of a polyurethane foam/spheroid artificial liver by using human hepatoblastoma cell line (Hep G2). Cell Transplant. 2003, 12, 51-58.
26. Vermeulen, N. P. E. Role of metabolism in chemical toxicity. In Cytochromes P450 Metabolic and Toxicological Aspects; Ioannides, C., Ed.; CRC Press: London, 1996; pp 29-53.
27. Wilkinson, G. R. Pharmacokinetics. In Goodman & Gilman's The Pharmacological Basis of Therapeutics, 10th ed.; Hardman, J. G., Limbird, L. E., Eds.; McGraw-Hill: New York, 2001; pp 3-30.
28. Gluud, C. Acute, serious drug-induced liver injury. J. Hepatol. 2002, 37, 675-677.
29. Larrey, D. Drug-induced liver diseases. J. Hepatol. 2000, 32 (1 Suppl), 77-88.
30. Omasa. T. Gene amplification and its application in cell and tissue engineering. J. Biosci. Bioeng. 2002, 94, 600-605.
31. Yoshikawa, T.; Nakanishi, F.; Ogura, Y.; Oi, D.; Omasa, T.; Katakura, Y.; Kishimoto, M.; Suga, K. Flow cytometry: an improved method for the selection of highly productive gene-amplified CHO cells using flow cytometry. Biotechnol Bioeng. 2001, 74, 435-442.
32. Nyberg, S. L.; Mann, H. J.; Remmel, R. P.; Hu, W. S.; Cerra, F. B. Pharmacokinetic analysis verifies P450 function during in vitro and in vivo application of a bioartificial liver. ASAIO J. 1993, 39, M252-256.
33. Iwata, H.; Sajiki, T.; Maeda, H.; Park, Y. G.; Zhu, B.; Satoh, S.; Uesugi, T.; Ikai, I.; Yamaoka, Y.; Ikada, Y. In vitro evaluation of metabolic functions of a bioartificial liver. ASAIO J. 1999, 45, 299-306.
34. Hoener, B. A. Predicting the hepatic clearance of xenobiotics in humans from in vitro data. Biopharm. Drug Dispos. 1994, 15, 295-304.
35. Sy, B.; Ciaccia, A.; Li, W.; Roberts, A.; Okey, A.; Kalow, W.; Tang, K. Modeling of human hepatic CYP3A4 enzyme kinetics, protein, and mRNA indicates deviation from log-normal distribution in CYP3A4 gene expression. Eur. J. Clin. Pharmacol. 2002, 58, 357-365.
36. Nelson, L. J.; Newsome, P. N.; Howie, A.; Fadoke, P. W.; Dabos, K. J.; Walker, S. W.; Hayes, P. C.; Plevris, J. N. An improved ex vivo method of primary porcine hepatocyte isolation for use in bioartificial liver systems. Eur. J. Gastroenterol. Hepatol. 2000, 12, 923-930.
37. Osredkar, J.; Vrhovec, I.; Jesenovec, N.; Kocijancic, A.; Prezelj, J. Salivary free testosterone in hirsutism. Ann. Clin. Biochem. 1989, 26, 522-526.
38. Matsumura, T.; Takamura, M.; Enosawa, N.; Suzuki, S.; Amamiya, H.; Yoshida, N. Immobilization of animal cells on ultrafine fiber fabrics and immobilized animal cells. Jpn. Kokai Tokkyo Koho JP 2001309782, 2001.
39. Ueda, Y.; Iwata, H.; Paek, H. J.; Ko, I. K.; Shimooka, Y.; Katsura, N.; Ikai, I.; Yamaoka, Y.; Ikada, Y. Bioartificial liver with whole blood perfusion. ASAIO J. 2003, 49, 401-406.